← Eichor
Study identifier: NCT07524270 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effera Dose Response: Women's Health

Condition: Womens Health · Menstrual Symptoms  ·  Sponsor: Helaina Inc.

PhaseNA
Planned participants160
Who can joinFemale, 18 Years to 40 Years
Healthy volunteersYes

About this study

The goal of this clinical trial is to learn if a human equivalent lactoferrin supplement (effera®) can improve menstrual symptoms, mood, and quality of life in healthy women aged 18-40. The main questions it aims to answer are: Does effera® reduce the severity of menstrual symptoms? Does effera® improve mood, gastrointestinal symptoms, and overall well-being? Researchers will compare three different doses of effera® to a placebo (a look-alike supplement with no active ingredient) to see if the supplement improves these outcomes. Participants will: Take the assigned supplement (effera® or placebo) daily for 12 weeks Complete online questionnaires about menstrual symptoms, mood, and health Optionally share sleep and activity data from a wearable device

This description comes directly from the study's public registry record.

Talk to the study team

Chad Kerksick, PhD  ·  (650) 206-8006  ·  chad.kerksick@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

AlethiosSan Francisco, California, United StatesRecruiting
Alethios, Inc.San Francisco, California, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07524270